The S&P 500 and the Dow Jones Industrial Average were little changed on Friday after a mixed jobs report, while tech stocks lifted the Nasdaq to a record intraday high
The Nasdaq was on track to be the biggest gainer in Wall Street’s first trading week of the year, rising about 2.2 percent. The S&P was set to gain 1.3 percent and the Dow 0.6 percent.
the Dow Jones Industrial Average .DJI was up 3.89 points, or 0.02 percent, at 19,903.18, the S&P 500 .SPX was up 1.67 points, or 0.07 percent, at 2,270.67 and the Nasdaq Composite index .IXIC was up 21.24 points, or 0.39 percent, at 5,509.17.
Los Angeles, California headquartered Puma Biotechnology Inc.’s stock finished Thursday’s session 3.65% lower at $33.00 with a total trading volume of 850,187 shares. The Company’s shares have advanced 7.49% on an YTD basis. The stock is trading 15.73% below its 50-day moving average. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have a Relative Strength Index (RSI) of 45.09.
Sangamo Biosciences, Inc (NASDAQ:SGMO), with shares high 7.25% is now trading at $3.70. The Stock is active as 757,117.00 shares changed hands versus its average volume of 1.02M shares. For investors focus on the performance of the stocks so the SGMO showed weekly ahead performance of 18.97% which was maintained for the month at 11.29%. Correspondingly the negative performance for the quarter was remained - 27.22% and if took notice on yearly performance that was -58.03% whereas the year to date performance halted at 13.11%.
Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, declares that it has changed its corporate name, from “Sangamo BioSciences, Inc.” to “Sangamo Therapeutics, Inc.” Sangamo common stock will continue to trade on the NASDAQ Global Select Market under the current ticker symbol: “SGMO.” The new corporate name underscores Sangamo’s focus on clinical development of genomic therapies using the Company’s industry-leading platform technologies across genome editing, gene therapy, gene regulation and cell therapy.
“Our new name, Sangamo Therapeutics, reflects our commitment to advance our groundbreaking science into the clinic for the development of transformative therapies for serious, genetically tractable diseases,” said Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo’s newly designated CEO. “Our scientists are pioneers in their fields, and over the last two decades, they have developed the most advanced, flexible and precise tools available for genomic therapies. With new leadership, a flattened organizational structure, overhauled administration processes and clear direction from our board, Sangamo now has the focus and capabilities in clinical science and product development to advance this powerful scientific platform into clinical development.”
Sangamo will be participating in the JP Morgan Healthcare Conference being held next week in San Francisco. A presentation at the conference by CEO Sandy Macrae is planned for Wednesday, January 11th, 2017 at 4:30 pm Pacific Time.
Mirati Therapeutics, Inc. (NASDAQ:MRTX), with shares fell -1.27% is now trading at $5.82. The Stock is active as 741,189.00 shares changed hands versus its average volume of 139,492.00 shares. The stock is going forward its 52 week low with 32.39% and lagging behind from its 52 week high price with - 80.46%. MRTX last month stock price volatility remained 6.76%.
Mirati Therapeutics, Inc. (MRTX) recently declared the pricing of an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60 per share. In addition, and in lieu of common stock, Mirati is offering to funds associated with Boxer Capital, LLC pre-funded warrants to purchase up to an aggregate of 7,258,263 shares of common stock at a purchase price of $5.599 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are predictable to be about $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is predictable to close on or about January 11, 2017, subject to customary closing conditions. Mirati has granted the underwriters a 30-day option to purchase up to an additional 652,526 shares of common stock in connection with the public offering. All of the securities are being offered by Mirati.
Mirati anticipates to use the net proceeds from this offering for general corporate purposes, counting for clinical development of glesatinib, sitravatinib and mocetinostat, in addition to for development of preclinical programs and working capital.
